Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026)

Recursion Pharmaceuticals has reported Long-Term Deferred Tax for 3 years, with the latest figure at $957000.0 in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax fell 52.22% year-over-year to $957000.0; the trailing twelve-month figure through Mar 2026 stood at $957000.0 (down 52.22% YoY), and the FY2025 full-year result was $957000.0, down 50.52% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $957000.0, roughly flat from $957000.0 in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $2.0 million in Q1 2025, with the low at $957000.0 in Q2 2025.
• Historically, Long-Term Deferred Tax has averaged $1.3 million across 3 years, with a median of $957000.0 in 2025.
• Annual changes were most pronounced in 2025 — Long-Term Deferred Tax tumbled 50.52% — and 2026, when it slumped 52.22%.
• Recursion Pharmaceuticals' Long-Term Deferred Tax stood at $1.9 million in 2024, then plunged by 50.52% to $957000.0 in 2025, then changed by 0.0% to $957000.0 in 2026.
• The last three Long-Term Deferred Tax figures came in at $957000.0 (Q1 2026), $957000.0 (Q4 2025), and $957000.0 (Q3 2025), per Business Quant data.